Guggenheim Securities, the investment banking arm of Guggenheim Partners, has formed a strategic alliance with Australia’s ...

Guggenheim has initiated coverage of Metsera (NASDAQ:MTSR) with a buy rating, citing the company's obesity drug candidates.

Guggenheim has initiated Metsera at buy saying that the biotech's pipeline of injectable and oral nutrient stimulated hormone ...

Guggenheim analyst Michael Morris maintained a Buy rating on Paramount Global Class B (PARA – Research Report) yesterday and set a price target ...

Looking for something to do in New York? Catch the superstar Diana Ross at the Kings Theater, learn all about crankies, or ...

The performance artist Marina Abramovic celebrated the announcement of a new cultural center in a private home designed by ...

LG and the Guggenheim New York proudly announce Ayoung Kim as the 2025 LG Guggenheim Award recipient. Kim is the third artist to be recognized as part of the LG Guggenheim Art and Technology ...

Set on La Gorce Island, a Miami Beach residence listed for $88 million—dubbed Okto—spans nearly 16,000 square feet with 260 ...

Guggenheim initiated coverage of Sportradar (SRAD) with a Buy rating and $27 price target Discover the Best Stocks and Maximize Your Portfolio: ...

Wingstop (NASDAQ:WING – Get Free Report) was upgraded by analysts at Guggenheim from a “neutral” rating to a “buy” rating in ...

Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...

Guggenheim restated their buy rating on shares of Guardant Health (NASDAQ:GH – Free Report) in a report released on Monday ...